Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02229461 · ClinicalTrials.gov registry record · Phase 1
Naproxen Sodium/ASA Platelet Study
A Phase 1 study of Hematology, sponsored by Bayer.
- Completed
- Registry status
- Phase 1
- Development phase
- 117
- Enrollment target
- 1
- Study location
NCT02229461: Completed Phase 1 study of Hematology, sponsored by Bayer.
NCT02229461 is a Phase 1 study of Hematology that has completed, run by Bayer. The registered enrollment target is 117 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02229461, a Phase 1 study of Hematology, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 117 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine if administration of naproxen sodium 220 mg maintains the platelet inhibitory effect of a low dose Immediate Release Aspirin (IR ASA) regimen.
Primary Outcome
Inhibition of serum TXB2 at specified time point was calculated using the percentage of reduction from baseline as follows: Inhibition (%) = 100 × (Baseline Value - Post-baseline Value) / Baseline Value. For primary analysis, the mean and the lower bound of the corresponding one-sided 95% Confidence Interval (CI) were calculated.
Conditions Studied
Interventions
- DRUG Naproxen Sodium (Aleve, BAY117031)
- DRUG Acetylsalicylic Acid (Aspirin, BAYE4465)
Study Locations (1)
Texas
- - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2015-02 |
| Est. Completion | 2015-05 |
| Phase | Phase 1 |
What the finished NCT02229461 record still lists
NCT02229461 is an interventional study that assigns participants to a tested intervention. The registered 117 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% higher).
The record links to 1 condition, with Hematology appearing as the primary indexed condition, and to 2 interventions - of which Naproxen Sodium (Aleve, BAY117031) is the first listed.
NCT02229461 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT02229461 about?
NCT02229461 is a clinical study titled "Naproxen Sodium/ASA Platelet Study". To determine if administration of naproxen sodium 220 mg maintains the platelet inhibitory effect of a low dose Immediate Release Aspirin (IR ASA) regimen.
What is the current status of trial NCT02229461?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 117 participants. The study started on 2015-02. Estimated completion is 2015-05.
What conditions does trial NCT02229461 study?
This clinical trial studies the following conditions: Hematology.
What interventions are being tested in trial NCT02229461?
The interventions under investigation include: Naproxen Sodium (Aleve, BAY117031) (DRUG), Acetylsalicylic Acid (Aspirin, BAYE4465) (DRUG).
Who is sponsoring clinical trial NCT02229461?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02229461 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematology
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02229461's enrollment target sits among peer trials
117 499th of 2000 higher than 1,500 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03539822 · 117 participants · Phase 1
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
- NCT03786692 · 117 participants · Phase 2
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
- NCT04479696 · 117 participants · NA
Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors
- NCT04940585 · 117 participants · NA
ROSE in Sunset Park
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia